Cryoport, Inc. (CYRX)
Cryoport, Inc. (CYRX) from its SEC filings: 2025 revenue $176.2 million (+12% vs the year before), net margin 44%, free cash flow -$25.0 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $176.2 million |
| Revenue growth | +12% |
| Net income | $78.3 million |
| Net margin | 44.4% |
| Free cash flow | -$25.0 million |
| Diluted EPS | $1.40 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +8% |
| Cash | $269.3 million |
| Long-term debt | $1.3 million |
| Share count, 1 year | +1% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.